UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 of 15(d) of the
Securities Exchange Act of 1934
January 19, 2010
------------------------------------------------
Date of Report (date of earliest event reported)
CYTODYN INC.
----------------------------------------------------
Exact name of Registrant as Specified in its Charter
Colorado 000-49908 75-3056237
--------------------------- --------------- ---------------------------
State or Other Jurisdiction Commission File IRS Employer Identification
of Incorporation Number Number
1511 Third Street, Santa Fe, New Mexico 87505
----------------------------------------------------------
Address of Principal Executive Offices, Including Zip Code
(505) 988-5520
--------------------------------------------------
Registrant's Telephone Number, Including Area Code
Not applicable
-----------------------------------------------------------
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 REGULATION FD DISCLOSURE.
The Company issued a press release on January 19, 2010 (attached hereto as
Exhibit 99) regarding Open Enrollment for Clinical Trial of Cytolin(R).
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Businesses Acquired.
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Shell Company Transactions
Not Applicable.
(d) Exhibits
Exhibit 99 Press Release regarding the Company's Enrollment Open for
Clinical Trial of Cytolin(R) dated January 19, 2010
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTODYN INC.
Date: January 19, 2010 By: /s/ Allen D. Allen
-----------------------------
Allen D. Allen
President and CEO